Emerald Health Pharmaceuticals
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
Emerald Health Pharmaceuticals was a San Diego clinical-stage drug company founded in 2017, developing novel patented small molecules derived from synthetic cannabidiol (CBD) and cannabigerol (CBG) for diseases with unmet medical need, including neurodegenerative, autoimmune, inflammatory, and fibrotic disorders. Its lead candidate, EHP-101, was being tested in a Phase 2a trial for systemic sclerosis. The company was related to Canadian cannabis group Emerald Health Therapeutics.
02 / Emerald Health Pharmaceuticals FAILURE REASONS
Failure factors
The company could not secure financing or a buyer. Difficult biotech funding conditions, limited cash and restrictions on financing options contributed to the decision to liquidate.
03 / EVENT HISTORY
Events in the structured record
- Liquidation
The company dissolved in March 2023 under a liquidation plan and began discontinuing clinical programs and winding down operations.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Novel CBD/CBG-derived small-molecule drug pipeline
- 02
EHP-101 advanced into a Phase 2a systemic sclerosis trial
- 03
Fundraising failed in the brutal 2022–23 biotech market
- 04
Board approved liquidation Feb 2023; dissolved Mar 17, 2023 with $0.7M cash against $4.5M liabilities